Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRB NYSE:IBIO NASDAQ:JAGX NASDAQ:LIXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$4.87+3.8%$5.22$4.11▼$68.70$14.97M0.42151,978 shs116,147 shsIBIOiBio$0.82-0.9%$0.73$0.56▼$6.89$16.07M0.61.54 million shs563,945 shsJAGXJaguar Animal Health$1.63+1.9%$2.28$1.57▼$35.25$3.48M0.43137,111 shs102,798 shsLIXTLixte Biotechnology$4.45+13.8%$3.39$0.64▼$5.14$17.86M0.43132,789 shs218,605 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences+3.84%-0.20%+1.88%-35.33%-92.62%IBIOiBio-0.90%+3.38%+19.90%+6.54%-57.41%JAGXJaguar Animal Health+1.87%-9.44%-23.83%-62.18%-94.23%LIXTLixte Biotechnology+13.81%+30.50%+19.30%+277.12%+163.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences2.0394 of 5 stars3.32.00.00.02.01.70.6IBIOiBio1.2679 of 5 stars3.50.00.00.00.60.00.6JAGXJaguar Animal Health2.0863 of 5 stars3.53.00.00.02.10.00.6LIXTLixte Biotechnology0.1786 of 5 stars0.02.00.00.02.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.50Moderate Buy$375.007,600.21% UpsideIBIOiBio 3.00Buy$5.00511.47% UpsideJAGXJaguar Animal Health 3.00Buy$60.003,580.98% UpsideLIXTLixte Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest JAGX, CLRB, LIXT, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025CLRBCellectar BiosciencesRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$1.74 per shareN/AIBIOiBio$375K42.86N/AN/A$1.41 per share0.58JAGXJaguar Animal Health$11.69M0.30N/AN/A$2.02 per share0.81LIXTLixte BiotechnologyN/AN/AN/AN/A$0.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$44.58M-$19.91N/AN/AN/AN/A-486.67%-150.57%11/17/2025 (Estimated)IBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AJAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-344.16%-660.18%-77.42%11/12/2025 (Estimated)LIXTLixte Biotechnology-$3.59M-$1.29N/A∞N/AN/AN/A-222.90%11/10/2025 (Estimated)Latest JAGX, CLRB, LIXT, and IBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLRBCellectar Biosciences-$3.60-$3.39+$0.21-$3.39N/AN/A8/14/2025Q2 2025JAGXJaguar Animal Health-$7.13-$10.26-$3.13-$10.26$3.27 million$2.98 million8/7/2025Q2 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A2.152.15IBIOiBio0.051.761.76JAGXJaguar Animal Health2.440.950.59LIXTLixte BiotechnologyN/A1.841.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%IBIOiBio7.90%JAGXJaguar Animal Health12.04%LIXTLixte Biotechnology5.10%Insider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences5.04%IBIOiBio0.58%JAGXJaguar Animal Health4.55%LIXTLixte Biotechnology14.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences103.19 million3.03 millionOptionableIBIOiBio10019.66 million9.82 millionN/AJAGXJaguar Animal Health502.17 million2.08 millionNo DataLIXTLixte Biotechnology44.56 million3.89 millionNot OptionableJAGX, CLRB, LIXT, and IBIO HeadlinesRecent News About These Companies24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer TherapyAugust 27 at 8:15 AM | globenewswire.com24/7 Market News: LIXTE Targets Large, Unmet Oncology MarketsAugust 25, 2025 | globenewswire.com24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100August 19, 2025 | globenewswire.comLixte Biotechnology Raises $6.5M, Appoints New ManagementAugust 19, 2025 | msn.comLixte Biotechnology provides update on recent corporate activitiesAugust 18, 2025 | msn.comLIXTE Biotechnology Holdings Provides Corporate UpdateAugust 18, 2025 | globenewswire.com24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025August 14, 2025 | globenewswire.com24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025August 14, 2025 | finance.yahoo.com24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025August 14, 2025 | globenewswire.com24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury StrategyAugust 13, 2025 | globenewswire.comLIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include CryptocurrencyAugust 13, 2025 | globenewswire.comLixte Biotechnology Regains Nasdaq Compliance After FundraisingJuly 19, 2025 | theglobeandmail.comLIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing RequirementsJuly 16, 2025 | globenewswire.comSpartan Capital Securities, LLC Serves as Placement Agent in Lixte ...July 11, 2025 | morningstar.comMSpartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $5.0 Million Private Placement | MorningstarJuly 9, 2025 | morningstar.comMLixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering | MorningstarJuly 9, 2025 | morningstar.comMLixte Biotechnology raises $1.5 million in registered direct offeringJuly 9, 2025 | investing.comSpartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct OfferingJuly 9, 2025 | finance.yahoo.comSpartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct OfferingJuly 9, 2025 | globenewswire.comNew Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer TrialsJuly 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAGX, CLRB, LIXT, and IBIO Company DescriptionsCellectar Biosciences NASDAQ:CLRB$4.87 +0.18 (+3.84%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$4.86 0.00 (-0.10%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.iBio NYSE:IBIO$0.82 -0.01 (-0.90%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.80 -0.02 (-2.65%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Jaguar Animal Health NASDAQ:JAGX$1.63 +0.03 (+1.88%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.86%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Lixte Biotechnology NASDAQ:LIXT$4.45 +0.54 (+13.81%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$4.24 -0.21 (-4.61%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
